PolyMedix Hid Drug's Flaws Before $20M Stock Deal, Suit Says

Law360, New York (July 2, 2012, 5:21 PM EDT) -- PolyMedix Inc. was slapped with a lawsuit in Pennsylvania federal court Monday by a putative class of investors who say the experimental drug company misled the public about a flawed anti-stroke treatment in order to generate buzz for a $20 million stock offering.

The company and its top brass misled investors about clinical trials of PMX-60056, a compound intended to induce blood clotting in order to reduce the risk of stroke, according to the suit. In numerous public statements, PolyMedix executives downplayed clinical trial results linking...
To view the full article, register now.

Documents

Related

Sections

Case Information

Case Title

ANDERSON v. POLYMEDIX, INC. et al


Case Number

2:12-cv-03721

Court

Pennsylvania Eastern

Nature of Suit

Other Statutes: Securities/Commodities

Judge

MARY A. MCLAUGHLIN

Date Filed

July 2, 2012

Law Firms

Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.